Literature DB >> 21804582

PI3K pathway inhibitors approach junction.

David Holmes.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21804582     DOI： 10.1038/nrd3527

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  22 in total

1.  Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene.

Authors:  Hiroaki Itamochi; Misaki Kato; Mayumi Nishimura; Nao Oumi; Tetsuro Oishi; Muneaki Shimada; Shinya Sato; Jun Naniwa; Seiya Sato; Michiko Nonaka; Akiko Kudoh; Naoki Terakawa; Junzo Kigawa; Tasuku Harada
Journal:  Hum Cell       Date:  2013-02-21       Impact factor: 4.174

2.  High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions.

Authors:  Marsilius Mues; Laila Karra; Damia Romero-Moya; Anica Wandler; Matthew J Hangauer; Olga Ksionda; Yvonne Thus; Marthe Lindenbergh; Kevin Shannon; Michael T McManus; Jeroen P Roose
Journal:  Cell Rep       Date:  2019-04-09       Impact factor: 9.423

3.  Cytotoxic effects of natural and semisynthetic cucurbitacins on lung cancer cell line A549.

Authors:  Izabella Thaís Silva; Fabiana Cristina Geller; Lara Persich; Sabine Eva Dudek; Karen Luise Lang; Miguel Soriano Balparda Caro; Fernando Javier Durán; Eloir Paulo Schenkel; Stephan Ludwig; Cláudia Maria Oliveira Simões
Journal:  Invest New Drugs       Date:  2016-01-16       Impact factor: 3.850

Review 4.  Sox2: regulation of expression and contribution to brain tumors.

Authors:  Sheila Mansouri; Romina Nejad; Merve Karabork; Can Ekinci; Ihsan Solaroglu; Kenneth D Aldape; Gelareh Zadeh
Journal:  CNS Oncol       Date:  2016-05-27

5.  Development of a High-Throughput Screening Assay to Identify Inhibitors of the Lipid Kinase PIP5K1C.

Authors:  Brittany D Wright; Catherine Simpson; Michael Stashko; Dmitri Kireev; Emily A Hull-Ryde; Mark J Zylka; William P Janzen
Journal:  J Biomol Screen       Date:  2014-12-22

Review 6.  Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies.

Authors:  Kim M Keppler-Noreuil; Victoria E R Parker; Thomas N Darling; Julian A Martinez-Agosto
Journal:  Am J Med Genet C Semin Med Genet       Date:  2016-11-18       Impact factor: 3.908

7.  An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.

Authors:  Pradip De; Nandini Dey; Breanne Terakedis; P Leif Bergsagel; Zhi Hua Li; Daruka Mahadevan; Joseph R Garlich; Suzanne Trudel; Milan T Makale; Donald L Durden
Journal:  Cancer Chemother Pharmacol       Date:  2013-01-25       Impact factor: 3.333

8.  Synthesis and characterization of a novel prostate cancer-targeted phosphatidylinositol-3-kinase inhibitor prodrug.

Authors:  Daniele Baiz; Tanya A Pinder; Sazzad Hassan; Yelena Karpova; Freddie Salsbury; Mark E Welker; George Kulik
Journal:  J Med Chem       Date:  2012-09-10       Impact factor: 7.446

Review 9.  Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care.

Authors:  Mizuki Nishino; Hiroto Hatabu; Lynette M Sholl; Nikhil H Ramaiya
Journal:  Radiographics       Date:  2017 Sep-Oct       Impact factor: 5.333

Review 10.  The function, mechanisms, and role of the genes PTEN and TP53 and the effects of asbestos in the development of malignant mesothelioma: a review focused on the genes' molecular mechanisms.

Authors:  Leonardo Vinícius Monteiro de Assis; Mauro César Isoldi
Journal:  Tumour Biol       Date:  2013-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.